在中度至重度的COVID-19治疗后额外皮质类固醇的有效性:一项观察性研究
Yosuke Fukuda1,2, Kaoru Mochizuki2, Miharu Ijichi2
1Department of Medicine, Division of Respiratory Medicine and Allergology, Yamanashi Red Cross Hospital, Fujikawaguchiko-machi, JPN.
Cureus
|September 11, 2023
概括
在为COVID-19治疗德甲 (DEX) 后增加额外的皮质类固醇 (AC) 并没有改善患者的治疗结果. 这种治疗策略还可能增加持久症状的患者住院时间和感染风险.
科学领域:
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲 (DEX) 对COVID-19有效,但有些患者会出现残留症状或肺部阴影.
- 在这种情况下,额外的皮质类固醇 (AC) 治疗的疗效尚不清楚.
研究的目的:
- 在COVID-19患者中评估AC的有效性,这些患者在DEX治疗后有持续的呼吸道症状或氧气需求.
主要方法:
- 在34名COVID-19患者的回顾性观察性研究中,在DEX治疗后满足了特定标准.
- 14名接受AC (AC组) 的患者与20名不接受AC (NC组) 的患者进行比较.
- 分析90天死亡率,氧气治疗需求,住院时间和不良事件.
主要成果:
- 在90天死亡率 (35.7%与25.0%) 或在出院时需要氧气方面,两组之间没有显著差异.
- AC组的住院时间明显长 (中位数为33天而不是7.5天).
- 在AC组中,感染率明显高于AC组 (p = 0.005).
结论:
- 在甲后增加额外的皮质类固醇并不能改善COVID-19患者的临床结果.
- 交流疗法可能导致长时间住院,并增加严重感染的风险.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
295
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
295
COPD: Management Using Bronchodilators and Corticosteroids
241
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
241
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
Myocarditis III: Medical Management
7
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
7
Pericarditis III: Medical Management
13
The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...
13
Pleural Effusion II: Symptoms and Management
208
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
208


